A Phase 2A, Randomized, Double-Blind, Placebo-Controlled, Multiple Center, Multiple-Dose Study to Assess the Efficacy and Safety of ZYN002 Administered as a Transdermal Gel to Patients with Knee Pain due to Osteoarthritis

Trial Profile

A Phase 2A, Randomized, Double-Blind, Placebo-Controlled, Multiple Center, Multiple-Dose Study to Assess the Efficacy and Safety of ZYN002 Administered as a Transdermal Gel to Patients with Knee Pain due to Osteoarthritis

Completed
Phase of Trial: Phase II

Latest Information Update: 14 Aug 2017

At a glance

  • Drugs Cannabidiol (Primary)
  • Indications Pain
  • Focus Therapeutic Use
  • Acronyms STOP 1
  • Sponsors Zynerba Pharmaceuticals
  • Most Recent Events

    • 14 Aug 2017 Status changed from active, no longer recruiting to completed as per Zynerba Pharmaceuticals media release.
    • 14 Aug 2017 Primary endpoint has not been met. (To evaluate the efficacy of ZYN002 administered as a transdermal gel for 12 weeks as treatment for knee pain due to osteoarthritis (OA) of the knee.), as reported in a Zynerba Pharmaceuticals media release.
    • 14 Aug 2017 Top line results presented in a Zynerba Pharmaceuticals media release
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top